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Abstract:  Fetal  microchimerism  (FMc)  is  predicted  to  promote  offspring  fitness  and  
maternal  microchimerism  (MMc)  is  predicted  to  promote  maternal  fitness.  Offspring  
and  mothers  benefit  from  each  other’s  health.  Therefore,  the  effects  of  microchimeric  
cells  should  usually  not  be  detrimental  to  their  host,  but  the  evolutionary  interests  of  
mothers  and  offspring  diverge  when  there  is  competition  among  siblings  for  maternal  
investment.  Fetal  cells  in  mothers’  bodies  could  benefit  their  own  offspring  at  the  
expense  of  sibs  by  promoting  lactogenesis  or  by  extending  the  interbirth  interval.  
  
Fetal  cells  colonize  maternal  bodies  during  pregnancy  and  maternal  cells  colonize  fetal  
bodies.  The  engrafted  cell  populations  can  persist  for  the  remainder  of  the  mothers’  and  
offspring’s  lives.  Moreover,  the  presence  in  a  woman’s  body  of  her  mother’s  cells  
(maternal  microchimerism/MMc)  and  her  offspring’s  cells  (fetal  microchimerism/FMc)  
raises  the  possibility  of  secondary  engraftment.  Fetuses  could  feasibly  be  colonized  by  
cells  derived  from  maternal  grandmothers  or  older  sibs,  perhaps  even  by  cells  of  great  
grandmothers  and  matrilineal  aunts  and  uncles  (tertiary  engraftment).  As  a  result,  most  
human  bodies  contain  cells  derived  from  two  or  more  related  genetic  individuals.  This  
intriguing  phenomenon,  of  ubiquitous  kin  chimerism,  has  attracted  little  attention  from  
evolutionary  biologists  even  though  inclusive  fitness  theory  was  developed  to  explain  
the  evolution  of  interactions  among  kin.1  A  recent  paper  has  taken  a  first  step  toward  
addressing  this  neglect.2  
From  an  evolutionary  perspective,  engrafted  cells  are  subject  to  natural  selection  
for  their  effects  on  the  inclusive  fitness  of  their  donor  not  their  host.3  Mother  and  child  
have  a  mutual  interest  in  each  other’s  well-­‐‑being  because  a  child’s  fitness  is  enhanced  by  
having  a  healthy  mother  and  a  mother’s  fitness  by  the  production  of  healthy  offspring.  
Natural  selection  will  therefore  tend  to  eliminate  negative  effects  of  FMc  and  MMc  on  
host  health  and  favor  positive  effects.    
An  important  caveat  should  be  mentioned.  All  genes  of  an  infant  benefit  from  
maternal  health,  even  though  some  genes  are  absent  from  the  mother,  because  all  genes  
benefit  from  the  mother’s  care  of  the  infant.  By  contrast,  only  those  of  a  mother’s  genes  
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inherited  by  an  infant  benefit  from  that  infant’s  survival.  The  effects  of  a  non-­‐‑inherited  
maternal  haplotype  (NIMH)  on  an  offspring’s  fitness  are  irrelevant  to  the  propagation  of  
that  haplotype  except  in  so  far  as  these  effects  have  consequences  for  other  individuals  
who  carry  the  haplotype.  Thus,  an  NIMH  would  increase  in  frequency  if  it  caused  the  
early  demise  of  embryos  without  its  copies  if  this  sped  the  conception  of  replacement  
embryos  with  its  copies.4  Such  an  embryocidal  effect  could  occur  across  the  maternal-­‐‑
fetal  interface  or  be  mediated  by  MMc  within  offspring  bodies.  
‘Spiteful’  effects  of  NIMHs  are  strongly  disfavored  by  natural  selection  if  the  
effects  are  also  experienced  by  offspring  that  inherit  the  haplotype.  Therefore,  effects  of  
maternal  genes  that  do  not  discriminate  between  offspring  with  and  without  their  copies  
should  promote  the  health  of  all  offspring  because  each  offspring  has  an  equal  chance  of  
inheriting  a  maternal  gene’s  copies.  Most  maternal  effects  are  likely  to  be  of  this  benign  
type  because  of  the  rarity  of  genetic  ‘self-­‐‑recognition’  and  because  natural  selection  at  
unlinked  loci  will  tend  to  suppress  haplotypic  nepotism.  The  discussion  that  follows  will  
assume  maternal  genes  have  non-­‐‑discriminatory  effects.  
Siblings  share  genes.  Therefore,  genes  of  offspring  benefit  from  a  mother’s  
continued  reproduction.  Maternal  genes  of  an  offspring  obtain  this  inclusive  fitness  
benefit  from  all  of  the  mother’s  other  offspring  whereas  paternal  genes  benefit  from  full-­‐‑
sibs,  but  not  from  half-­‐‑sibs  sired  by  a  different  father.  The  evolutionary  interests  of  
mothers  and  offspring  are  not  identical,  however,  because  natural  selection  favors  
offspring  who  value  themselves  more  highly  than  their  sibs.5  Genes  expressed  in  
offspring  will  favor  maternal  investment  in  their  own  offspring  relative  to  its  sibs  
whereas  genes  expressed  in  mothers  will  favor  allocation  of  care  and  attention  to  
whichever  offspring  gains  the  greatest  benefit.  Thus,  genes  expressed  in  mothers  (or  
MMc)  will  evolve  to  maximize  the  mother’s  number  of  surviving  offspring  whereas  
genes  expressed  in  offspring  (or  FMc)  will  evolve  to  favor  their  own  offspring’s  survival  
even  at  some  greater  cost  to  its  sibs.    
MMc  might  benefit  mothers  by  reducing  offspring  demands,  perhaps  favoring  a  
more  sleepy  and  compliant  child,  or  by  reducing  sibling  rivalry  and  promoting  sibling  
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solidarity.  FMc  creates  the  possibility  that  mother–offspring  conflict  and  sibling  rivalry  
can  be  played  out  within  the  mother’s  body.2  There  are  many  ways  that  FMc  could  
benefit  fetuses  prenatally,  including  mobilization  of  maternal  reserves  for  use  by  the  
fetus,  but  there  are  fewer  ways  that  FMc  could  cause  mothers  to  discriminate  postnatally  
in  favor  of  the  microchimeric  cells’  own  offspring.    
One  route  for  postnatal  manipulation  of  mothers  would  be  for  FMc  to  promote  
differentiation  of  alveolar  epithelium  in  the  maternal  breast,  or  to  inhibit  mammary  
involution,  thereby  enhancing  and  maintaining  the  milk  supply  for  the  suckling  infant.2  
By  the  production  of  growth  or  differentiation  factors,  a  relatively  small  number  of  fetal  
cells  could  have  a  large  effect  on  mammary  differentiation.  Consistent  with  this  
possibility,  cells  with  Y  chromosomes  are  commonly  found  in  human  breasts.6,7  These  
cells  could  contribute  to  protection  against  breast  cancer  if  their  effects  on  lobular  
differentiation  were  to  reduce  the  pool  of  mammary  stem  cells.  An  area  for  future  study  
is  the  relation  between  microchimerism  and  inflammatory  disorders  of  the  breast.  
Expression  of  inflammation-­‐‑associated  genes  is  upregulated  in  parous  breasts  for  at  least  
a  decade  after  pregnancy8  and  gigantomastia  and  sclerosing  lymphocytic  lobulitis  are  
associated  with  autoimmune  disease.9,  10  
Longer  delays  until  the  birth  of  a  subsequent  child  reduce  child  mortality  under  
conditions  of  resource  scarcity.11  Thus,  FMc  could  benefit  infants  by  delaying  the  birth  of  
a  younger  sib.2  There  are  multiple  possible  scenarios:  fetal  cells  in  the  maternal  breast  
could  promote  lactogenesis  and  longer  duration  of  lactational  amenorrhea  (see  above);  
fetal  cells  in  the  maternal  ovary  could  interfere  with  ovulation;  or  fetal  cells  in  the  
maternal  endometrium  could  interfere  with  implantation  of  subsequent  embryos.  A  
recent  study  found  foreign  cells  in  the  endometrium  of  parous  women12  and  FMc  is  
more  readily  detected  in  women  who  have  experienced  a  pregnancy  loss.13  
Discriminatory  effects  of  maternal  or  paternal  haplotypes  of  FMc  against  subsequent  
embryos  that  do  not  inherit  their  copies  are  worth  consideration.2  
A  key  question  is  whether  immigrant  cells  perform  specialized  functions  in  host  
bodies  or  simply  behave  as  they  would  in  their  body  of  origin.  If  cells  do  not  distinguish  
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between  resident  and  immigrant  roles,  then  cellular  functions  will  be  subject  to  selection  
on  their  average  effects  in  the  two  roles  weighted  by  the  strength  of  selection  in  each  
role.  Functions  in  the  resident  role  would  tend  to  predominate  because  resident  cells  
vastly  outnumber  immigrant  cells.  If,  on  the  other  hand,  immigrant  cells  have  evolved  
specialist  functions,  then  these  functions  would  be  expected  to  promote  the  fitness  of  the  
genetic  individual  from  whom  the  cells  originated.  Microchimerism  is  an  evolutionarily  
ancient  phenomenon  that  has  been  detected  in  humans,  monkeys,  mice,  rats,  pigs,  cattle  
and  dogs.14–18  There  has  been  ample  time  for  the  evolution  of  specialist  functions.  
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